Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus New information about the natural history of cervical dysplasia and the role of human papillomavirus (HPV) in cervical cancer, as well as the development of new technologies for cervical cancer screening, prompted the American College of Obstetricians and Gynecologists (ACOG) to develop new guidelines for the management of abnormal cervical cytology and histology. One is to start screening at a slightly older age, and the other is to preferentially recommend a type of screening test called an HPV test. The American College of Obstetricians and Gynecologists (ACOG) has issued new cervical cancer screening guidelines that recommend women begin screening for cervical cancer at 21 years of age. No, the recommendations for this age group are the same as before. The United States Preventive Services Task Force (USPSTF), American Cancer Society (ACS) and American College of Obstetricians and Gynecologists (ACOG) have all issued guidelines on cervical cancer screening. The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. ACOG Releases Guidelines for Management of Abnormal Cervical - AAFP The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. recommendations for the practice of colposcopy. Cervical cancer screening may include Pap tests, testing for a virus called human papillomavirus (HPV), or both. The Pap test detects changes in cervical cells before they become abnormal or cancerous. a reflex HPV test. Copyright 2023 American Academy of Family Physicians. If you have had a hysterectomy in which your cervix was removed and: You have a history of cervical cancer or moderate to severe cervical changesContinue to have screening for 20 years after your surgery. 5. Clinical judgment should always be used when applying a guideline to an individual patient because it is impossible Rarely screened (>5 years ago): Patients who are not currently in surveillance and have not undergone screening within the past 5 years. Trends over time in Pap and Pap-HPV cotesting for cervical cancer screening. These recommendations also do not apply to individuals with in utero exposure to diethylstilbestrol or those who have a compromised immune system (eg, individuals with human immunodeficiency virus). The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer The COVID-19 pandemic initially resulted in most elective procedures being put on hold, leading to many people not getting screened for cancer. Hepatitis C in pregnancy: screening, treatment, and management. Thats why ACS recommends starting screening at age 25. Retrieved April 12, 2021. The standard approach is to do a Pap test, but there is also a new FDA-approved test, called dual stain. We also have seen great development of new technologies like HPV testing and improvement in some of the secondary tests that are used for following up after screening. %PDF-1.6
%
The WHO also updated their guidelines for HPV testing, recommending that women in their 20s get tested every 5 years instead of annually as before. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. These recommendations are in line with those of the World Health Organization (WHO), which says that all women should start getting annual Paps at age 25, and then switch to every 3 years starting at age 30. Inadequate cervical cancer screening remains a significant problem in the United States, with persistent health inequities across the entire spectrum of cervical cancer care 10 17 19 . And it detects a lot of minor changes that have a very low risk of turning into cancer. ScreeningCervical cancer screening and abnormal result management recommendations for immunocompromised individuals without HIV use the guidelines developed for people living with HIV144: Cytology only screening should begin within 1 year of first insertional sexual activity Continue cytology only annually for 3 years Continue every 3 years (cytology only) until the age of 30 years Cytology alone or cotesting every 3 years after the age of 30 years for the patient's lifetime.Management of Abnormal ResultsIn immunocompromised patients of any age, colposcopy referral is recommended for all results of HPV-positive ASC-US or higher. Data is temporarily unavailable. cervical cancer screening tests and cancer precursors. Erin Nelson, MD; Akiva Novetsky, MD, MS; Rebecca Perkins, MD; Jeffrey Quinlan, MD; Mona Saraiya, MD; Debbie Saslow, Visit our ABOG MOC II collection. ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors have been published. undergo colposcopy. Adolescents with ASC-US and a negative high-risk HPV test result should have a Papanicolaou test after 12 months. For example, an ASC-US cytology should trigger Two HPV tests have been approved by the Food and Drug Administration (FDA) for use as a primary HPV test, meaning it is not part of an HPV/Pap cotest. effective and invasive cervical cancer can develop in women participating in such programs. Other guidelines, statements, and recommendations related to anogenital and HPV-related diseases. incorporation of future technologies as well. Those with cytologic abnormalities or persistent HPV infection at one year should undergo colposcopy. The new guidelines are based on the most recent scientific evidence and take into account the latest HPV vaccines. J Low Genit Tract Dis 2020;24:10231. individual patient based on their current results and past history. 0
This is an important change that is related to HPV vaccines. Surgical excision or destruction of cervical tissue in nulliparous adolescents may harm fertility and cervical competency. Adolescents with AGC should be referred to a subspecialist with expertise in managing cervical dysplasia and should have colposcopy and endocervical sampling. Adolescents with HSIL and biopsy-confirmed CIN 2 may be monitored without intervention if they have adequate colposcopy and normal histology test results on endocervical assessment. J Womens Health (Larchmt) 2019;28:2449. What I Tell Every Patient About the HPV Vaccine, Why Annual Pap Smears Are History But Routine Ob-Gyn Visits Are Not, Copyright 2023 American College of Obstetricians and Gynecologists, Privacy Statement
found when histology or cytology is inconclusive such as a result of LSIL cannot rule out HSIL. (Endorsed March 2018). UpToDate hbbd``b`Z$EA/@H+/H@O@Y> t(
American College of Obstetricians and Gynecologists Obstet Gynecol 2020;136:e1521. No industry funds were used in the The ASCCP Management Guidelines App & Web Application is Now Available Streamline navigation of the ASCCP Risk Based Management Consensus Guidelines with the NEW ASCCP Management Guidelines App Evidence-based management guidelines Simple navigation Uncomplicated guidance The PDFKEG's Acog PAP Guidelines Algorithm 2020 is an easy-to-use, interactive document that helps clinicians manage patients with suspected obstructive sleep apnea. Limited access to primary hrHPV testing is of particular concern in rural and under-resourced communities and among communities of color, which have disproportionately high rates of cervical cancer incidence, morbidity, and mortality 8 9 10 . This was a large consensus effort involving several clinical organizations, federal agencies, and patient representatives. A study of partial human papillomavirus genotyping in support of There are a few risks that come with cervical cancer screening tests. Screening with an HPV test alone was not recommended by ACS in 2012 because that approach wasnt yet approved by FDA. Reducing Cancers Global Burden: A Conversation with NCIs Dr. Satish Gopal, If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. Available at: Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. If you are 65 or olderYou do not need screening if you have no history of cervical changes and either three negative Pap test results in a row, two negative HPV tests in a row, or two negative co-test results in a row within the past 10 years. Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. high quality evidence, and in these situations the guidelines have, by necessity, been based on consensus expert The American Cancer Society Guidelines for the Prevention and Early opinion. All rights reserved. Theres alsothe possibility of added anxiety and other emotions from incorrect, or false-positive, test results. Atypical squamous cells of undetermined significance (ASC-US) may indicate HPV infection. Adult and adolescent women with HSIL should have colposcopy with endocervical assessment. Wolters Kluwer Health
ET). Primary HPV testing: testing with HPV testing alone as a screening or surveillance test. Updated United States consensus guidelines for management of cervical screening abnormalities are needed to American Society for Colposcopy and Cervical Pathology. ASCCP and the Society of Gynecologic Oncology endorse this Practice Advisory. Rather than consider screening test results in isolation, the new guidelines use current and past results, and other factors, to create individualized assessments of a patients immediate risk of precancer (CIN3+), or 5-year risk of progressing to precancer or cancer. Clinical Practice Listserv (Members Only), Colposcopy Education Completion Program (formerly CMP), new iOS& Android mobile apps and the Web application. Available at: https://www.nsgc.org/d/do/4584. No part of this publication may be reproduced, stored in a retrieval system, posted on the internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher. Even if you are not due for cervical cancer screening, you should still see your ob-gyn regularly for birth control counseling, vaccinations, health screenings, prepregnancy care, and the latest information about your reproductive health. No. If youve had a series of normal screening test results over a long period of time, then you can stop screening at age 65. Adequate negative prior screening test results are defined as three consecutive negative cytology results, two consecutive negative cotesting results, or two consecutive negative hrHPV test results within 10 years before stopping screening, with the most recent test occurring within the recommended screening interval for the test used (1, 5). Lower Anogenital Squamous Terminology (LAST): this term refers to two-tiered pathology criteria for
Who developed these guidelines? Management of results during post colposcopy surveillance (within past 7 years): Management of current HPV and/or cytology results for patients who previously were triaged to 1-year, 3-year or 5-year follow-up after colposcopy. Adolescents with low-grade squamous intraepithelial lesions (LSIL) can be monitored with cytologic screening at six and 12 months or a high-risk HPV test at 12 months as an alternative to immediate colposcopy. In both tests, cells are taken from the cervix and sent to a lab for testing: An HPV test looks for infection with the types of HPV that are linked to cervical cancer. As vaccination coverage increases and more vaccinated individuals reach the age to initiate cervical cancer screening, HPV prevalence is expected to continue to decline 12 13 . For additional quantities, please contact sales@acog.org or call toll-free from U.S.: (800) 762-2264 or (240) 547-2156 . AGE TO BEGINSCREENINGRECOMMENDATION Under 21 years of ageScreening not recommended 21 - 29 years of age 30 - 65 years of age 65 years of age Status post hysterectomy for benign disease Liquid-based Pap test every 3 years2,3,4 0yr2"c`
`<0 "!.XXL*H1Y0&P9H261o K6A$Q$iE30120e`+ Bq
For example, HPV primary testing or Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Currently, there are 3 options available for cervical cancer screening: the Pap-only test, the Pap-HPV cotest, and the high-risk HPV-only test. your express consent. Pausing Therapy for Early-Stage Breast Cancer to Get Pregnant, Lung-Sparing Surgery Effective for Some with Lung Cancer, U.S. Department of Health and Human Services, Pap test every 3 years, HPV test every 5 years, or HPV/Pap cotest every, No screening if a series of prior tests were normal, No screening if a series of prior tests were normal and not at high risk for cervical cancer. 1. Are Cancer Patients Getting the Opioids They Need to Control Pain? Updated guidelines for management of cervical cancer screening abnormalities. If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription. these guidelines. All participating consensus organizations, including the Obstetrics & Gynecology137(1):184-185, January 2021. Cervical cytology in minors often is obtained during contraception counseling or confidential screening for sexually transmitted diseases (STDs), which may take place without the knowledge of the parent or guardian. Confirm your email to receive complimentary access to the ASCCP Management Guidelines web application. Mobile App - ASCCP Email I want to receive newsletters and other promotional materials from ASCCP via email. Follow-up can be individualized; a conservative approach would be colposcopy or cytology every four to six months. ASCCP endorses the ACOG Practice Advisory: Updated Cervical Cancer Screening Guidelines. Screening Guidelines - ASCCP Screening Guidelines USPSTF Screening Guidelines ASCCP endorses the United States Preventative Services Task Force (USPSTF) cervical cancer screening guidelines. patient would be a candidate for expedited management. No industry funds were used in the development of You may be trying to access this site from a secured browser on the server. It is not intended as a statement of the standard of care, nor does it comprise all proper treatments or methods of care. may email you for journal alerts and information, but is committed
See the full list of organizations (below) that participated in the consensus process. Updated guidelines were needed to incorporate these changes. If you are 30 to 65You can choose one of three options: Have a Pap test and an HPV test (co-testing) every 5 years. Routine cervical cancer screening is very effective for preventing cervical cancer and deaths from the disease. Available at: Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, et al. Screening recommended every 3 years for women 21-29. Read common questions on the coronavirus and ACOGs evidence-based answers. 2, March 2021. Details of the statistical methods are described in the publication Li C., et al. The algorithm contains tabs with videos and links to additional resources designed to make it easier to guide your next visit. Follow-up after treatment: Management of current HPV and/or cytology results for patients who have previously been treated for dysplasia. 104 0 obj
<>
endobj
J Low Genit Tract Dis 2020;24:10231. If HPV testing is not performed on ASC-US results, then repeat cytology in 6 to 12 months is recommended, with colposcopy referral for ASC-US or higher. The new ACOG guidelines also say that women over 30 years old should have a Pap test every three years if they are healthy, have been having regular annual check-ups and do not have symptoms. Release of the 2020 American Cancer Society Cervical Cancer Screening Guidelines On July 30th, the American Cancer Society (ACS) released its updated guidelines for "Cervical Cancer Screening for . They will then examine it under a microscope in order to detect any abnormal changes in your cervical cells that could be cancerous or pre-cancerous lesions (precancers). Guidelines New Management Guidelines Are Here ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors have been published. Risk-based management allows clinicians to better identify which patients will likely go on to develop pre-cancer and which patients can return to surveillance. long-term utility of the guidelines. Its a simple test that can save your life, and its recommended for women between 21 and 65 years old. Women with ASC-US who have had liquid-based cytologic screening should be tested for high-risk HPV, and those with positive results (i.e., presence of high-risk HPV DNA) should have colposcopy. JAMA 2018;320:67486. To ensure the risk estimates generated from KPNC data are generalizable (portable), we also estimated risks using data from the Centers for Disease Control and Prevention (CDC), the New Mexico Pap Study, and two clinical trials. Data from clinical trial, cohort, and modeling studies demonstrate that among average-risk patients aged 2565 years, primary hrHPV testing and co-testing detect more cases of high-grade cervical intraepithelial neoplasia than cytology alone, but hrHPV-based tests are associated with an increased risk of colposcopies and false-positive results 1 6 7 . PDF Cervical Cancer Screening Guidelines: What's new? Routine screening applies Repeat Pap test in six and 12 months or high-risk HPV test alone in 12 months, Colposcopy, endocervical assessment, possible endometrial evaluation, Pap test at six and 12 months or high-risk HPV test at 12 months; colposcopy for any abnormality, Close follow-up at four- to six-month intervals (cytology or colposcopy)*. And if you have an incorrect result, you may end up getting unnecessary follow-up tests or even unnecessary treatment. Practice Advisory. The new Risk-Based Management Consensus Guidelines have several important differences from the 2012 Guidelines, NCI Division of Cancer Epidemiology & Genetics. For adolescents with CIN 1, management without therapy provides the best balance between risk and benefit. Transformation Zone (LLETZ), and cold knife conization. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Data from Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. The acog pap guidelines algorithm 2021 pdf Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. UpToDate better identify which patients will likely go on to develop pre-cancer and which patients may be indicated to return Cancer 2017;123:104450. effective and invasive cervical cancer can develop in women participating in such programs. All rights reserved. and patient advocates, convened by ASCCP; they are designed to safely triage individuals with abnormal cervical This bimonthly monograph series is available online to ACOG members at https://www.acog.org/clinical/journals-and-publications/clinical-updates. Currently, there are two hrHPV tests approved by the FDA for primary screening in individuals aged 25 years and older. Pap screening may end at age 65 if the Pap history is unremarkable and the patient is low risk. The abnormal changes are called dysplasia; over time, these changes may progress to cervical cancer if left untreated. While ACOG makes every effort to present accurate and reliable information, this publication is provided as is without any warranty of accuracy, reliability, or otherwise, either express or implied. Available at: Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. MMWR Morb Mortal Wkly Rep 2021;70:2935. Available at: Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al.